Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
Top Cited Papers
- 6 July 2009
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (2) , 219-234
- https://doi.org/10.1038/bmt.2009.141
Abstract
The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.Keywords
This publication has 80 references indexed in Scilit:
- Risk-Adjusted Outcome Measurement in Pediatric Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2008
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007
- Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemiaBlood, 2007
- Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison studyThe Lancet, 2007
- Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell TherapyJournal of Clinical Oncology, 2006
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in EuropeBone Marrow Transplantation, 2006
- Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancyBlood, 2005
- Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute LeukemiaNew England Journal of Medicine, 2004
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in EuropeBone Marrow Transplantation, 2002
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998Bone Marrow Transplantation, 1998